Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Cardio-oncology
Cardiotoxicity
Heart failure
Risk factors
Risk prediction
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
05
01
2020
revised:
13
05
2020
accepted:
25
05
2020
pubmed:
29
5
2020
medline:
10
6
2021
entrez:
29
5
2020
Statut:
ppublish
Résumé
This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
Identifiants
pubmed: 32463967
doi: 10.1002/ejhf.1920
pmc: PMC8019326
mid: NIHMS1663326
doi:
Substances chimiques
Androgen Antagonists
0
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1945-1960Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL141466
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : Department of Health
ID : 06/303/98
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA233610
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Circulation. 2015 Jun 2;131(22):1981-8
pubmed: 25948538
Mayo Clin Proc. 2014 Sep;89(9):1287-306
pubmed: 25192616
Blood. 2010 Jul 8;116(1):22-6
pubmed: 20339094
JAMA Intern Med. 2015 Jun;175(6):1007-17
pubmed: 25915855
J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9
pubmed: 17686822
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
Blood Adv. 2017 May 15;1(13):802-811
pubmed: 29296724
J Am Coll Cardiol. 2014 Mar 4;63(8):809-16
pubmed: 24291281
PLoS One. 2016 Dec 2;11(12):e0165262
pubmed: 27911951
Clin Investig Arterioscler. 2014 Jul-Aug;26(4):200-3
pubmed: 24725681
JAMA Netw Open. 2019 Aug 2;2(8):e198890
pubmed: 31397860
J Clin Oncol. 2015 Dec 10;33(35):4210-8
pubmed: 26371140
Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66
pubmed: 22997448
Ann Oncol. 2012 Apr;23(4):897-902
pubmed: 21828361
J Card Fail. 2012 Feb;18(2):113-9
pubmed: 22300778
BMJ. 2017 May 23;357:j2099
pubmed: 28536104
J Am Soc Hypertens. 2014 Nov;8(11):791-9
pubmed: 25455004
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Lancet Oncol. 2018 Sep;19(9):e447-e458
pubmed: 30191849
J Am Coll Cardiol. 2019 Dec 24;74(25):3099-3108
pubmed: 31856966
J Card Fail. 2009 Oct;15(8):651-7
pubmed: 19786253
Eur J Heart Fail. 2018 Dec;20(12):1721-1731
pubmed: 30191649
J Clin Oncol. 2013 Nov 20;31(33):4222-8
pubmed: 24127446
J Clin Oncol. 2007 Sep 1;25(25):3859-65
pubmed: 17646669
Am J Hematol. 2015 Nov;90(11):1060-4
pubmed: 26284693
J Natl Cancer Inst. 2010 Jan 6;102(1):39-46
pubmed: 19996060
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):870-878.e1
pubmed: 28803825
JACC Heart Fail. 2013 Feb;1(1):72-8
pubmed: 24621801
BMJ. 2009 Dec 08;339:b4606
pubmed: 19996459
Oncology. 2014;86(1):16-21
pubmed: 24335608
Blood. 2018 Jul 26;132(4):393-404
pubmed: 29567798
Lancet. 2017 Mar 25;389(10075):1195-1205
pubmed: 28215665
Int J Cardiol. 2019 Aug 1;288:124-127
pubmed: 31029498
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
Circulation. 2004 Jun 8;109(22):2749-54
pubmed: 15148277
Contemp Oncol (Pozn). 2013;17(2):190-5
pubmed: 23788989
J Clin Oncol. 2017 Dec 1;35(34):3837-3843
pubmed: 28922087
PLoS One. 2014 Jan 29;9(1):e87671
pubmed: 24489948
Circulation. 2016 Feb 2;133(5):537-41
pubmed: 26831435
Medicine (Baltimore). 2016 Nov;95(44):e5195
pubmed: 27858859
Ann Oncol. 2001 Aug;12(8):1067-73
pubmed: 11583187
J Clin Oncol. 2008 Nov 10;26(32):5204-12
pubmed: 18838713
Eur Heart J. 2019 Jun 7;40(22):1756-1763
pubmed: 30085070
Haematologica. 2016 Oct;101(10):1200-1207
pubmed: 27470600
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Tumour Biol. 2016 Mar;37(3):3379-87
pubmed: 26449821
Cardiooncology. 2017 Jun 1;3:4
pubmed: 32154000
J Clin Oncol. 2012 Nov 1;30(31):3792-9
pubmed: 22987084
Lancet Oncol. 2016 May;17(5):612-21
pubmed: 27083332
J Clin Oncol. 2012 May 1;30(13):1429-37
pubmed: 22473161
Eur J Cancer. 2014 Aug;50(12):2162-70
pubmed: 24930624
BJU Int. 2014 Dec;114(6b):E82-E89
pubmed: 24612110
J Clin Oncol. 2002 Mar 1;20(5):1215-21
pubmed: 11870163
J Am Heart Assoc. 2014 Feb 28;3(1):e000472
pubmed: 24584736
Cancer. 2003 Jun 1;97(11):2869-79
pubmed: 12767102
Lancet. 2007 Dec 15;370(9604):2011-9
pubmed: 18083403
Eur J Cancer. 2019 Sep;119:97-106
pubmed: 31437754
Leukemia. 2013 Jun;27(6):1310-5
pubmed: 23459450
J Oncol Pharm Pract. 2016 Apr;22(2):242-7
pubmed: 25567518
N Engl J Med. 2013 Nov 14;369(20):1970
pubmed: 24224635
Eur J Haematol. 2016 Jul;97(1):25-32
pubmed: 26331915
Curr Cardiol Rev. 2011 Nov;7(4):214-20
pubmed: 22758622
Leukemia. 2016 May;30(5):1044-54
pubmed: 26837842
Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93
pubmed: 25239940
J Clin Oncol. 2019 Aug 1;37(22):1946-1955
pubmed: 31188726
Ann Oncol. 2009 Sep;20(9):1535-1542
pubmed: 19474115
Am J Cardiol. 2015 Aug 1;116(3):442-6
pubmed: 26071994
J Am Heart Assoc. 2018 Aug 7;7(15):e008637
pubmed: 30371238
J Am Coll Cardiol. 2000 Aug;36(2):517-22
pubmed: 10933366
Ann Intern Med. 2016 Aug 2;165(3):161-6
pubmed: 27295519
Cancer. 2015 Jan 15;121(2):311-9
pubmed: 25236375
Ann Oncol. 2009 May;20(5):816-27
pubmed: 19153118
J Clin Oncol. 2008 Mar 10;26(8):1231-8
pubmed: 18250349
J Clin Oncol. 2007 Sep 1;25(25):3808-15
pubmed: 17664460
Ann Intern Med. 1979 Nov;91(5):710-7
pubmed: 496103
J Clin Oncol. 2010 Sep 1;28(25):3910-6
pubmed: 20679614
J Card Fail. 2016 Jun;22(6):433-8
pubmed: 27079675
J Clin Oncol. 2006 Sep 20;24(27):4448-56
pubmed: 16983113
J Clin Oncol. 2004 May 15;22(10):1864-71
pubmed: 15143078
J Clin Oncol. 2017 Mar 10;35(8):878-884
pubmed: 28199174
Oncologist. 2009 Sep;14(9):862-70
pubmed: 19726453
NPJ Precis Oncol. 2018 May 8;2:13
pubmed: 30202791
J Clin Oncol. 2016 Sep 10;34(26):3157-65
pubmed: 27458291
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825